Chargement en cours...
Should we treat acute hepatitis C? A decision and cost-effectiveness analysis
It is not standard practice to treat patients with acute hepatitis C virus (HCV) infection. However, as the incidence of HCV in the United States continues to rise, it may be time to re-evaluate acute HCV management in the era of direct-acting antiviral agents (DAAs). In this study a microsimulation...
Enregistré dans:
| Publié dans: | Hepatology |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5826841/ https://ncbi.nlm.nih.gov/pubmed/29059461 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.29611 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|